RBC Capital Reiterates Outperform on Biogen, Maintains $340 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Biogen (NASDAQ:BIIB) and maintained a $340 price target.
June 02, 2023 | 2:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams reiterated an Outperform rating on Biogen and maintained a $340 price target.
The reiteration of an Outperform rating and maintenance of a $340 price target by RBC Capital analyst Brian Abrahams indicates a positive outlook for Biogen's stock in the short term. This news is highly relevant and important for investors, as it suggests potential upside for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100